ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe.
I Vaz-Luis, M Masiero, G Cavaletti...
https://pubmed.ncbi.nlm.nih.gov/35963481/Actively Recruiting
Led by Masaryk Memorial Cancer Institute · Updated on 2026-11-03
200
Participants Needed
1
Research Sites
16 weeks
Total Duration
This research aims to evaluate a questionnaire designed to assess adverse effects in cancer survivors after completing curative treatment for breast and prostate cancer. The goal is to detect a wide range of physical, psychological, social, occupational, and financial impacts early, enabling better intervention and follow-up care. The study supports comprehensive care aligned with European Society for Medical Oncology recommendations, focusing on prevention and healthy lifestyles for survivors. Participants are randomly assigned to either active screening using the specific questionnaire combined with quality of life assessments or to quality of life screening alone. The active screening involves physician assessment based on patient responses, leading to interventions such as education, medication, or specialist referrals. The study spans enrollment and follow-up at six and twelve months to monitor outcomes. Throughout the study, participants complete questionnaires at baseline, six months, and twelve months to assess quality of life, questionnaire usability, and frequency of physician interventions. Researchers monitor how active screening affects quality of life and how well the questionnaire works in routine practice. Participants remain under regular follow-up during the 12 months after enrollment, with ongoing evaluations to support their health and well-being.
CONDITIONS
Cancer Survivors Program
L
Lenka Pavčíková, MUDr.
M
Martina Lojová, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Masaryk Memorial Cancer Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants are randomly assigned to receive either active screening for adverse effects using a specific questionnaire along with quality of life assessments or quality of life screening alone. Physicians assess responses and provide interventions as needed.
Assessments at baseline, 6 months, and 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
I Vaz-Luis, M Masiero, G Cavaletti...
https://pubmed.ncbi.nlm.nih.gov/35963481/Maryam B Lustberg, Raquel E Reinbolt, Charles L Shapiro
https://pubmed.ncbi.nlm.nih.gov/23008309/Marieke van Leeuwen, Jacobien M Kieffer, Fabio Efficace...
https://pubmed.ncbi.nlm.nih.gov/28490338/Michael G Culbertson, Kathleen Bennett, Catherine M Kelly...
https://pubmed.ncbi.nlm.nih.gov/33008323/Laxmi S Mehta, Karol E Watson, Ana Barac...
https://pubmed.ncbi.nlm.nih.gov/29437116/Marieke van Leeuwen, Olga Husson, Paola Alberti...
https://pubmed.ncbi.nlm.nih.gov/29866185/Simone Nardin, Edoardo Mora, Feba Mariam Varughese...
https://pubmed.ncbi.nlm.nih.gov/32612947/Isaac Allen, Hend Hassan, Eleni Sofianopoulou...
https://pubmed.ncbi.nlm.nih.gov/36765408/Deborah K Mayer, Shelly Fuld Nasso, Jo Anne Earp
https://pubmed.ncbi.nlm.nih.gov/28049573/Masaryk Memorial Cancer Institute
Lead Sponsor